title: Recent advances in the management of cutaneous lymphomas.
abstract: The treatment options for patients with primary cutaneous B- and T-cell lymphomas are as diverse as the diseases themselves, including both skin-directed and systemic therapies. Long-term remission can be attained in many cases; however, no treatment is curative with the possible exception of allogeneic stem cell transplant. Improved insight into the molecular biology and pathophysiology of these diseases has led to the development of novel drugs and targeted therapies, including monoclonal antibodies and antimetabolites, as well as improved radiotherapeutic techniques. We aim to summarize these new and emerging treatment modalities, and to outline how they may be integrated into the clinical management of patients with primary cutaneous lymphoma (CL).
authors.affiliation: Department of Dermatology, University Hospital Zürich, Switzerland.
authors.forename: Benedetta
authors.initials: B
authors.lastname: Belloni
authors.forename: Naomi
authors.initials: N
authors.lastname: Johansen
authors.forename: L Frank
authors.initials: LF
authors.lastname: Glass
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D019468:Disease Management; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy